Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bNAbs) although they express the epitopes recognized by bNAbs to the HIV envelope glycoprotein (Env). To understand whether and how Env immunogens interact with the predicted germline versions of known bNAbs, we screened a large panel (N:56) of recombinant Envs (from clades A, B and C) for binding to the germline predecessors of the broadly neutralizing anti-CD4 binding site antibodies b12, NIH45-46 and 3BNC60. Although the mature antibodies reacted with diverse Envs, the corresponding germline antibodies did not display Env-reactivity. Experiments conducted with engineered chimeric antibodies combining the mature and germline heavy and light chains, respectively and vice-versa, revealed that both antibody chains are important for the known cross-reactivity of these antibodies. Our results also indicate that in order for b12 to display its broad cross-reactivity, multiple somatic mutations within its VH region are required. A consequence of the failure of the germline b12 to bind recombinant soluble Env is that Env-induced B-cell activation through the germline b12 BCR does not take place. Our study provides a new explanation for the difficulties in eliciting bNAbs with recombinant soluble Env immunogens. Our study also highlights the need for intense efforts to identify rare naturally occurring or engineered Envs that may engage the germline BCR versions of bNAbs.
- Scripps Research Institute United States
- Massachusetts Institute of Technology United States
- UNIVERSITY OF WASHINGTON
- University of Mary United States
- UNIVERSITY OF WASHINGTON
10028 Institute of Medical Virology, 570, QH301-705.5, 2405 Parasitology, Antibody Affinity, 610, 610 Medicine & health, HIV Infections, HIV Antibodies, Lymphocyte Activation, Cell Line, Epitopes, 1311 Genetics, Neutralization Tests, 1312 Molecular Biology, Humans, Biology (General), Antigens, Viral, AIDS Vaccines, 2403 Immunology, B-Lymphocytes, 2404 Microbiology, env Gene Products, Human Immunodeficiency Virus, RC581-607, Antibodies, Neutralizing, Antibodies, Anti-Idiotypic, HEK293 Cells, CD4 Antigens, 2406 Virology, HIV-1, 570 Life sciences; biology, Immunoglobulin Light Chains, Immunologic diseases. Allergy, Immunoglobulin Heavy Chains, Research Article
10028 Institute of Medical Virology, 570, QH301-705.5, 2405 Parasitology, Antibody Affinity, 610, 610 Medicine & health, HIV Infections, HIV Antibodies, Lymphocyte Activation, Cell Line, Epitopes, 1311 Genetics, Neutralization Tests, 1312 Molecular Biology, Humans, Biology (General), Antigens, Viral, AIDS Vaccines, 2403 Immunology, B-Lymphocytes, 2404 Microbiology, env Gene Products, Human Immunodeficiency Virus, RC581-607, Antibodies, Neutralizing, Antibodies, Anti-Idiotypic, HEK293 Cells, CD4 Antigens, 2406 Virology, HIV-1, 570 Life sciences; biology, Immunoglobulin Light Chains, Immunologic diseases. Allergy, Immunoglobulin Heavy Chains, Research Article
2 Research products, page 1 of 1
- 2020IsAmongTopNSimilarDocuments
- 2013IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).179 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
